Benzinga··Globe NewswirePalvella Therapeutics Raises $230M in Upsized IPO to Fund Rare Disease Pipeline
Palvella Therapeutics closed $230M public offering at $125/share on February 27, 2026, fully exercising underwriter options to fund rare skin disease programs.
PVLAclinical-stagepublic offering